Shorter radiation may be just as good for rectal cancer patients

NCT ID NCT07258797

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two standard radiotherapy approaches—short-course (1 week) and long-course (several weeks)—given before surgery to people with locally advanced rectal cancer. The goal is to see which one works better at shrinking tumors and is easier for patients to tolerate. About 150 participants will be randomly assigned to one of the two treatments, and their outcomes will be tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Radiotherapy (short-course or long-course) plus chemotherapy (modified FOLFOX6 or mFOLFIRINOX)
What this could lead to
If successful, this study could show that a shorter radiotherapy course is just as effective as the longer one, potentially reducing treatment burden for patients with rectal cancer.
What could go wrong
This is a single-institution study with 150 participants, so results may not apply broadly. Both treatments are standard, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE RECTUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rajiv Gandhi Cancer Institute and Research Centre

    New Delhi, 110085, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.